BioVenture Forum showcases Oklahoma scientific achievementsPublished: Wednesday, April 5, 2017 By: Jim Stafford Source: NewsOK
Seated next to each other on a stage Tuesday morning at the Oklahoma Medical Research Foundation were the alpha and omega of Oklahoma City's Selexys Pharmaceuticals.
Dr. Rodger P. McEver and Russell Rother shared the stage as part of a panel discussion on “Relationship Dynamics in Startups: Early Stage to Exit” at the OMRF BioVenture Forum 2017. About 100 people attended the forum, including 35 venture capitalists from out of state.
Others on the panel, moderated by i2E Inc. CEO Scott Meacham, included Dr. Judith A. James, chair of OMRF's Arthritis and Clinical Immunology Research Program, and Mohan Purushothaman, president of Progentec Diagnostics.
“We're focusing on the handoff that has to occur in any successful launch of a new technology where you go from a researcher to a business person who is going to take the deal forward,” Meacham said. “That's a vital process and often time difficult process.”
McEver and Rother represented the beginning and successful exit from Selexys, which was acquired in late 2016 by Novartis Pharmaceuticals for $665 million, the largest life sciences deal in Oklahoma history.